Short‐term therapeutic effects ‐ progressive disease · patients with oesophageal cancer
Active cancer therapy combined with TCM showed no clear difference in short‐term therapeutic effects ‐ progressive disease compared with active cancer therapy (low certainty).
1 finding from 1 review
TCM symptoms ‐ total effectiveness · patients with oesophageal cancer
It is very uncertain whether active cancer therapy combined with TCM changes TCM symptoms ‐ total effectiveness compared with active cancer therapy (very low certainty).
1 finding from 1 review
Intervention not reported
Postoperative mortality · people with surgical treatment for periampullary or pancreatic carcinoma
The intervention showed no clear difference in postoperative mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Pancreatic fistula · people with surgical treatment for periampullary or pancreatic carcinoma
The intervention showed no clear difference in pancreatic fistula (low certainty).
1 finding from 1 review
Intervention not reported
DGE · people with surgical treatment for periampullary or pancreatic carcinoma
The intervention may leads to higher DGE (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · people with surgical treatment for periampullary or pancreatic carcinoma
The intervention showed no clear difference in overall survival (low certainty).
1 finding from 1 review
Intervention not reported
Intraoperative blood loss (millilitres) · people with surgical treatment for periampullary or pancreatic carcinoma
The intervention showed no clear difference in intraoperative blood loss (millilitres) (low certainty).
1 finding from 1 review
Intervention not reported
Red blood cell transfusion (units) · people with surgical treatment for periampullary or pancreatic carcinoma
The intervention showed no clear difference in red blood cell transfusion (units) (low certainty).
1 finding from 1 review
Intervention not reported
Operating time (minutes) · people with surgical treatment for periampullary or pancreatic carcinoma
The intervention showed no clear difference in operating time (minutes) (low certainty).
1 finding from 1 review
Intervention not reported
Induction of remission at 4 weeks · Childen (<16 years old)with active Crohn's disease
The intervention showed no clear difference in induction of remission at 4 weeks (low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · induction of remission in Crohn's disease
Briakinumab showed no clear difference in failure to induce clinical remission (Mannon 2004) CDAI (≤150 points) compared with placebo (low certainty).
2 findings from 1 review
Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) · induction of remission in Crohn's disease
Ustekinumab leads to lower failure to induce clinical response CDAI (≥100 point reduction) compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response (6 mg/kg subgroup) CDAI (≥100 point reduction) · induction of remission in Crohn's disease
Ustekinumab leads to lower failure to induce clinical response (6 mg/kg subgroup) CDAI (≥100… compared with placebo (high certainty).
1 finding from 1 review
Adverse events · induction of remission in Crohn's disease
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · induction of remission in Crohn's disease
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · induction of remission in Crohn's disease
Ustekinumab showed no clear difference in withdrawals due to adverse event compared with placebo (low certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · induction of remission in Crohn's disease
Briakinumab may leads to lower failure to induce clinical response (Mannon 2004) CDAI ‐ (≥100 point… compared with placebo (low certainty).
1 finding from 1 review
Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) · induction of remission in Crohn's disease
Briakinumab probably leads to lower failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (Panaccione 2010) · induction of remission in Crohn's disease
Briakinumab showed no clear difference in adverse events (Panaccione 2010) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (Panaccione 2010) · induction of remission in Crohn's disease
Briakinumab showed no clear difference in serious adverse events (Panaccione 2010) compared with placebo (low certainty).
1 finding from 1 review